AU Patent

AU2016265844B2 — Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations

Assigned to Memorial Sloan Kettering Cancer Center · Expires 2021-02-11 · 5y expired

What this patent protects

The present invention relates to methods of treating a vascular malformation in a subject expressing a gain-of-function mutation in a PIK3CA gene comprising administering, to the subject, an effective amount of an agent that inhibits phosphoinositide 3-kinase ("PI3K").

USPTO Abstract

The present invention relates to methods of treating a vascular malformation in a subject expressing a gain-of-function mutation in a PIK3CA gene comprising administering, to the subject, an effective amount of an agent that inhibits phosphoinositide 3-kinase ("PI3K").

Drugs covered by this patent

Patent Metadata

Patent number
AU2016265844B2
Jurisdiction
AU
Classification
—
Expires
2021-02-11
Drug substance claim
No
Drug product claim
No
Assignee
Memorial Sloan Kettering Cancer Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.